Wednesday December 18, 2019 0 comments
DENVER -- Colorado’s life sciences ecosystem raised $750 million in 2019, with funds from federal and state grants, successful financing rounds and acquisitions.
The record-breaking acquisition of Boulder-based Array BioPharma by Pfizer for $11.4 billion raises the Colorado financing total to $12.1 billion.
Clovis Oncology raised $175 million in clinical trial financing and Inscripta closed $125 million in Series D financing to fund commercialization of its digital genome engineering platform.
Additionally, more than 40 companies and institutions in Colorado received federal grants including funds from the National Institutes of Health (NIH), the U.S. Air Force and Small Business Innovative Research (SBIR) grants from the Small Business Administration.
The University of Colorado, National Jewish Health and Colorado State University were the state’s largest recipients of federal grants, all from the National Institutes of Health.
“Our ecosystem’s track record of successful financings and acquisitions highlights the global impact made by companies and organizations from Colorado,” said Jennifer Jones Paton, president and CEO of Colorado BioScience Association.
“Life sciences breakthroughs from our state change and save lives around the world. The record-breaking acquisition and successful fundraising demonstrate the strong interest in Colorado’s thriving life sciences ecosystem.”
“We are proud of the companies in our ecosystem that landed Advanced Industries Grants from the state of Colorado,” said Emily Roberts, CBSA VP.
“These funds are critical for our startup and mid-stage companies as they seek to prove out concepts and move into commercialization. We are committed to advocating for this important state funding of our innovators and job creators.”
The State of Colorado awarded 16 Advanced Industries grants to Colorado life sciences companies in 2019, with grants ranging from $20,000-$250,000.